证券日报网讯 12月17日，圣湘生物在互动平台回答投资者提问时表示，与阿里健康的合作是公司"三端 合一"模式与"医-检-药一体化"生态的深度协同。以"呼吸道病毒细菌12联检"项目为例，用户足不出户就 能完成专业级检测，平均3小时出报告，为其科学用药提供依据，有效缓解流感季就医压力。未来，双 方将以此次合作为起点，一方面推动居家快检服务的标准化建设与全国普及，另一方面共同探索更多感 染性疾病检测项目的居家化应用，助力构建"互联网+医疗+即时配送"的健康服务新生态。公司将携手 阿里健康共同推动严肃医疗的精准化与普惠化，驱动健康需求向主动化、消费化升级，引领健康消费向 严肃化、科学化、个性化方向发展，让量身定制的健康管理方案惠及每一位民众。 （编辑 任世碧） ...

Core Viewpoint - The collaboration between Shengxiang Bio and Alibaba Health aims to provide a home-based rapid testing service for respiratory diseases, addressing the rising flu activity in China and alleviating the pressure on healthcare facilities during the flu season [1][2]. Group 1: Company Collaboration - Shengxiang Bio has become the exclusive supplier for Alibaba Health's home-based rapid testing service, launching the "12-pathogen respiratory virus and bacteria test" project [1]. - The service allows users to receive professional-level testing results within an average of 3 hours without leaving their homes, thus providing a scientific basis for medication and reducing the burden on healthcare systems [1][2]. Group 2: Service Implementation - The home-based rapid testing service is initially available in four cities: Beijing, Shanghai, Guangzhou, and Hangzhou, with 17 service points established [2]. - Users can book the service through the Taobao app, where trained couriers will deliver sampling kits and assist in sample collection, which is then sent to certified laboratories for testing [2]. Group 3: Industry Trends - The home testing industry is experiencing rapid growth, with projections indicating that the market size for home self-testing in China will increase from 120 billion yuan to 280 billion yuan between 2025 and 2030, reflecting a compound annual growth rate of 18.5% [3]. - The partnership is seen as a significant step towards standardizing home rapid testing services and expanding the range of infectious disease testing applications in the future [3].